Plasma pTau blood biomarker tests (especially pTau217) for human clinical assessment of Alzheimer’s disease:
Dr. Carr currently offers the Labcorp pTau217 / amyloid beta 42/40 ratio and related Alzheimer’s blood biomarker testing as part of a robust dementia assessment or provides connections for testing through Apollo Health.
The Labcorp testing can be scheduled at their Patient Service Centers and has a good faith estimate of $398.40 for cash paying patients. Insurance billing is possible if the patient meets current guidelines for testing.
Other Laboratories developing or with developed early diagnostic Alzheimer’s Disease Tests.
| Company | Website |
|---|---|
| Apollo Health $799 with Nfl and GFAP | https://www.apollohealthco.com |
| BetterBrain $200+ | https://app.betterbrain.com/pre-registration?self |
| Function Health $499 + | https://www.functionhealth.com |
| Neurogen Biomarking $499 | https://neurogenbiomarking.com |
| True Health Labs $229 | https://truehealthlabs.com |
| C2N $1450 | multiplex mass spec based assay – can differentiate isoforms. |
| Alamar Biosciences CNS 120 panel -$TBD | Alamar Biosciences – immunoassays for the Brain isoform of pTau217 |
| MesoScale Diagnostics – Electro chemiluminescent Assay | S-PLEX Assay Platform | Meso Scale Discovery can assay Brain isoform of pTau217 |
| Quanterra Simoa Fluorescent System Aptamer/Antibody based Protein Asays | Alzpath pTau 217 Antibody ( not C terminal Isoform 0R, 1R, 3R or 4R specific) |